Wegovy vs Ozempic: Same Drug, Different Purpose

If you've spent any time researching GLP-1 medications, you've probably noticed that Wegovy and Ozempic come up constantly — sometimes in the same breath, sometimes as if they're completely different drugs. The confusion is understandable. Both are brand names for semaglutide, made by the same company (Novo Nordisk), and they look nearly identical. But they are not interchangeable, and which one you get prescribed matters — especially for insurance purposes.

Here's what you actually need to know.

The Short Answer

Wegovy and Ozempic contain the same active ingredient: semaglutide. The difference is in the approved dose and the approved medical indication.

• Wegovy is FDA-approved specifically for chronic weight management. Its maintenance dose goes up to 2.4 mg once weekly (FDA prescribing information, NDA 215256).
• Ozempic is FDA-approved for type 2 diabetes management and reducing cardiovascular risk in adults with type 2 diabetes and known heart disease. It's available in doses of 0.5 mg, 1 mg, and 2 mg once weekly (ozempic.com).

Same molecule. Different regulatory approvals. Different dose ceiling. That distinction drives almost every practical difference between the two.

How They Differ: Dose, Indication, and Pen Format

The dose gap matters more than it might sound. Ozempic tops out at 2 mg weekly for diabetes management (ozempic.com). Wegovy's standard maintenance dose is 2.4 mg weekly, reached through a gradual escalation that starts at 0.25 mg for the first four weeks (Wegovy prescribing information, FDA).

That higher maintenance dose is likely why Wegovy produced greater average weight loss in clinical trials — the STEP 1 trial found semaglutide 2.4 mg reduced body weight by approximately 15% over 68 weeks (NEJM, 2021). Ozempic was designed to improve blood sugar control, not maximize weight reduction. The weight loss people experience on Ozempic is real, but the drug wasn't dosed or studied with weight loss as the primary endpoint.

The pens themselves are also different — different delivery devices, different color coding, different pre-loaded cartridge concentrations — even though a pharmacist is filling both with semaglutide. You cannot swap pens between the two brands.

Additionally, Wegovy is now available in a once-daily oral tablet formulation — the oral version starts at 1.5 mg and escalates to a 25 mg maintenance dose — in addition to the once-weekly injection pen (wegovy.com). Ozempic is injection-only.

Insurance: Why the Approved Indication Changes Everything

This is where the Wegovy vs Ozempic distinction becomes financially significant.

Insurance plans cover medications based on their FDA-approved indication — not based on what a drug can also do. If you have obesity and you want insurance to pay for your semaglutide, you need Wegovy (approved for weight management), not Ozempic (approved for type 2 diabetes). Getting Ozempic covered for weight loss is very difficult because it's an off-label use for that purpose.

Conversely, if you have type 2 diabetes, your plan may cover Ozempic readily — but the same plan might deny Wegovy because you're using a weight loss drug for a diabetes-adjacent purpose.

For a deeper look at how prior authorization and coverage work, see our guides on does insurance cover Wegovy and navigating prior authorization.

Can You Use Ozempic for Weight Loss?

Technically, yes — off-label prescribing is legal and common in medicine. A licensed provider can prescribe Ozempic to someone without type 2 diabetes if they believe it's medically appropriate. Many people lost weight on Ozempic before Wegovy existed, and some providers still prescribe it this way.

But there are practical reasons this has become less common:

1. Insurance rarely covers it for weight loss since it's off-label for that use.
2. Wegovy's 2.4 mg dose may produce greater weight reduction than the doses available in Ozempic.
3. Using the FDA-approved medication for its labeled indication is standard clinical practice and simplifies insurance coverage.

If you're approaching telehealth with weight loss as your goal, you'll almost always be evaluated for Wegovy (or tirzepatide under Zepbound), not Ozempic. Ozempic in a weight loss context is mostly a legacy prescription pattern, not the current standard.

What Compounded Semaglutide Has to Do With Either

You've likely seen compounded semaglutide marketed online, sometimes starting well under $200 a month. Compounded semaglutide contains the same active ingredient as both Wegovy and Ozempic, but it's not FDA-approved as a finished product. Compounding pharmacies produce it under FDA oversight frameworks, but the formulation itself has not gone through the same clinical trial and approval process as Wegovy or Ozempic.

Compounded semaglutide is neither Wegovy nor Ozempic — it's a separate product that shares an active ingredient. It's also important to note that compounded semaglutide was only legal to dispense broadly while Wegovy was on the FDA shortage list. The FDA has since resolved that shortage (FDA drug shortages), and many compounders have had to adjust their programs as a result.

For a full breakdown of the regulatory and safety differences, see our article on compounded vs brand-name semaglutide.

Which One You'll Actually Be Prescribed via Telehealth

If you approach a telehealth provider today with weight loss as your goal, here's what typically happens:

• If you want brand-name semaglutide, the provider is likely to prescribe Wegovy — not Ozempic — because Wegovy is the FDA-approved option for your indication.
• If you want the lowest possible cost and are comfortable with a non-FDA-approved finished product, the provider may prescribe compounded semaglutide from a licensed pharmacy.
• If you have type 2 diabetes in addition to obesity, your provider might consider Ozempic depending on your insurance and clinical situation, but Wegovy and Zepbound (tirzepatide) are often preferred for the weight component.

Providers like Hims and Ro both offer brand-name Wegovy prescriptions and have teams that can help coordinate insurance coverage. Found also works across both brand-name and compounded options depending on your situation.

For patients focused on cost who have already researched the compounded route, Eden and Enhance MD are two providers worth comparing.

Wegovy vs Ozempic: Side-by-Side

	Wegovy	Ozempic
Active ingredient	Semaglutide	Semaglutide
FDA-approved indication	Chronic weight management	Type 2 diabetes; cardiovascular risk reduction
Approved doses	0.25 mg → 2.4 mg (injection); 1.5 mg → 25 mg (oral, once-daily) (wegovy.com)	0.5 mg, 1 mg, 2 mg (injection only)
Maintenance dose	2.4 mg weekly (injection)	Up to 2 mg weekly
Covered for weight loss?	Yes, with prior auth on many plans	Rarely — off-label use for weight loss
Maker	Novo Nordisk	Novo Nordisk

The Bottom Line: How to Choose

The choice between Wegovy and Ozempic isn't really yours to make — it's made by your diagnosis, your insurance plan, and your prescriber. But here's how to think about it:

Go for Wegovy if: Weight loss is your primary goal, you don't have type 2 diabetes, and you want the FDA-approved option for that indication. This is what most telehealth providers prescribe by default for weight loss without a diabetes diagnosis. If you have insurance coverage worth pursuing, Wegovy is the drug to pursue it with.

Ozempic may apply if: You have type 2 diabetes and weight management is a secondary goal, or your provider has a specific clinical reason to prescribe it. In this case, insurance coverage for the diabetes indication may already exist.

Consider compounded semaglutide if: Brand-name pricing is out of reach, you've read the regulatory background, and you understand it is not FDA-approved as a finished product. Compare providers carefully — pricing and pharmacy sourcing vary significantly.

If you're still weighing your options, our provider quiz can help narrow down which telehealth platform fits your insurance status, budget, and medication preference.